Ticker Details
Fate Therapeutics, Inc. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.
IPO Date:	October 1, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$168.41M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.56 | 3.56%
Avg Daily Range (30 D):	$0.05 | 4.49%
Avg Daily Range (90 D):	$0.05 | 4.09%

Institutional Daily Volume
Avg Daily Volume:	.92M
Avg Daily Volume (30 D):	1.68M
Avg Daily Volume (90 D):	1.6M

Trade Size
Avg Trade Size (Sh.):	118
Avg Trade Size (Sh.) (30 D):	271
Avg Trade Size (Sh.) (90 D):	291

Institutional Trades
Total Institutional Trades:	3,465
Avg Institutional Trade:	$2.74M
Avg Institutional Trade (30 D):	$1.18M
Avg Institutional Trade (90 D):	$1.05M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.79M
Avg Closing Trade (30 D):	$1.2M
Avg Closing Trade (90 D):	$1.2M
Avg Closing Volume:	204.96K

News

Feb 16, 2026 @ 6:00 PM IPSC-derived NK Cells Clinical Trial Pipeline Gain... Source: Delveinsight

Jan 23, 2026 @ 5:56 PM Breaking Barriers: How 2026’s Top Clinical ... Source: Equity Insider

Oct 26, 2025 @ 3:30 PM Fate Therapeutics Presents New Clinical Data at AC... Source: Fate Therapeutics

May 28, 2025 @ 9:54 PM Fate Therapeutics Announces Phase 1 Data Presentat... Source: N/A

Apr 2, 2025 @ 8:01 PM Fate Therapeutics Reports New Employee Inducement ... Source: N/A

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-1.33	$-.27	$-.29
Diluted EPS	$-1.33	$-.27	$-.29
Revenue	$7.14M	$1.74M	$1.91M
Gross Profit
Net Income / Loss	$-156.09M	$-32.25M	$-34.07M
Operating Income / Loss	$-174.73M	$-34.74M	$-36.97M
Cost of Revenue
Net Cash Flow	$2.71M	$-.63M	$5.19M
PE Ratio